Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | PNMT | P11086 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11758388 | 0.81 | TSHR (0.52) | TAAR1LMNAAKR1B1POLBSMN1; SMN2 | |
| SCHEMBL5247984 | 0.81 | CALM1 (0.52) | TAAR1LMNAAKR1B1TSHRKMT2A | |
| SCHEMBL673238 | 0.80 | TAAR1 (0.70) | TAAR1LMNAAKR1B1POLBSMN1; SMN2 | |
| SCHEMBL9456771 | 0.79 | HTT (0.55) | TAAR1LMNAAKR1B1POLBSMN1; SMN2 | |
| SCHEMBL27977720 | 0.78 | TAAR1 (0.52) | TAAR1LMNAAKR1B1POLBSMN1; SMN2 | |
| SCHEMBL1007397 | 0.78 | TAAR1 (0.52) | TAAR1LMNAAKR1B1POLBSMN1; SMN2 | |
| SCHEMBL18462099 | 0.77 | TAAR1 (0.58) | TAAR1LMNAAKR1B1POLBSMN1; SMN2 | |
| SCHEMBL8593028 | 0.77 | TAAR1 (0.58) | TAAR1LMNAAKR1B1POLBSMN1; SMN2 | |
| SCHEMBL2570362 | 0.77 | TAAR1 (0.46) | TAAR1LMNAAKR1B1POLBSMN1; SMN2 | |
| SCHEMBL9440191 | 0.75 | TAAR1 (0.40) | TAAR1LMNAAKR1B1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400520-A1 | CATALYST FOR OLEFIN POLYMERIZATION AND METHOD FOR PRODUCING OLEFIN POLYMER | The University of Tokyo (JP) | 2024-07-17 | — | — | EP | disclosed |
| WO-2023037849-A1 | CATALYST FOR OLEFIN POLYMERIZATION AND METHOD FOR PRODUCING OLEFIN POLYMER | 国立大学法人 東京大学 | 2023-03-16 | — | — | WO | disclosed |
| US-20100144872-A1 | New Methylenebisphenyl Compounds Useful in the Treatment of Inflammation | BIOLIPOX AB | 2010-06-10 | — | — | US | disclosed |
| US-20040248963-A1 | Prodrugs of excitatory amino acids | ELI LILLY AND COMPANY | 2004-12-09 | — | — | US | disclosed |
| US-6620940-B1 | Heterocyclic nitrogen/sulfur compounds used as chemical intermediates for drugs such as 3-chloro-4-(furan-2-yl)-1,2,5 -thiadiazole | ELI LILLY AND COMPANY | 2003-09-16 | — | — | US | disclosed |
| US-6372945-B1 | OXIDIZING BENZYL SULFIDE, REACTING BENZYL SULFOXIDE FORMED WITH STRONG BASE TO FORM BENZYLIC ANION, CONDENSING ANION WITH BENZALDEHYDE, REACTING CONDENSATION PRODUCT WITH ACID CHLORIDE TO PRODUCE ESTER, TREATING ESTER WITH STRONG BASE | ELI LILLY AND COMPANY | 2002-04-16 | — | — | US | disclosed |
| EP-0830356-B1 | PROCESS FOR THE SYNTHESIS OF BENZO(b)THIOPHENES | LILLY CO ELI (US) | 2001-08-22 | — | — | EP | disclosed |
| EP-0859770-B1 | PROCESS FOR THE SYNTHESIS OF BENZO b]THIOPHENES | LILLY CO ELI (US) | 1999-12-08 | — | — | EP | disclosed |
| US-5925680-A | Synthetic excitatory amino acids | ELI LILLY AND COMPANY (US) | 1999-07-20 | — | — | US | disclosed |
| US-5925782-A | Synthetic excitatory amino acids | ELI LILLY AND COMPANY (US) | 1999-07-20 | — | — | US | disclosed |
| EP-0859770-A4 | — | — | 1998-10-07 | — | — | EP | disclosed |
| EP-0859770-A1 | PROCESS FOR THE SYNTHESIS OF BENZO b]THIOPHENES | ELI LILLY AND COMPANY (US) | 1998-08-26 | — | — | EP | disclosed |
| US-5750566-A | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | ELI LILLY AND COMPANY (US) | 1998-05-12 | — | — | US | disclosed |
| US-5659087-A | CHEMICAL INTERMEDIATES FOR 2-ARYLBENZOTHIOPHENES | ELI LILLY AND COMPANY (US) | 1997-08-19 | — | — | US | disclosed |
| US-5606075-A | CYCLIZATION IN THE PRESENCE OF AN ACID CATALYST | ELI LILLY AND COMPANY (US) | 1997-02-25 | — | — | US | disclosed |
| WO-1996040676-A1 | PROCESS FOR THE SYNTHESIS OF BENZO[b]THIOPHENES | ELI LILLY AND COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5569772-A | CHEMICAL INTERMEDIATES | ELI LILLY AND COMPANY (US) | 1996-10-29 | — | — | US | disclosed |
| US-5514826-A | INTERMEDIATES FOR 2-ARYLBENZO(B)THIOPHENES | ELI LILLY AND COMPANY (US) | 1996-05-07 | — | — | US | disclosed |
| US-5512701-A | REACTING SULFOXIDE DERIVATIVE WITH A SILYATING AGENT TO FORM SULFENATE SILYL ESTER, OPTIONALLY REACTING INTERMEDIATE WITH AN AMINE AND/OR A MERCAPTAN | ELI LILLY AND COMPANY (US) | 1996-04-30 | — | — | US | disclosed |
| EP-0696577-A1 | Synthetic excitatory amino acids | ELI LILLY AND COMPANY (US) | 1996-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248963-A1 | Prodrugs of excitatory amino acids | SLC1A2, SLC1A1, SLC1A3 | TAAR1 172/4885LMNA 4003/4885AKR1B1 1113/4885 |
| US-20100144872-A1 | New Methylenebisphenyl Compounds Useful in the Treatment of Inflammation | LTC4S, LTB4R2, LTB4R | TAAR1 1435/4885LMNA 1200/4885AKR1B1 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.